Diabetes, obesity drug studied for effect on Alzheimer’s

May 25, 2023

From social media to ads featuring an earworm jingle, it’s hard to escape hearing about Ozempic. Hailed for its game-changing effect on diabetes and obesity, semaglutide, the generic medication sold under the brand name Ozempic, is now being studied for its effectiveness on another deadly disease — Alzheimer’s. The Glenn Biggs Institute for Alzheimer’s and […]

Statement from the Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases at The University of Texas Health Science Center at San Antonio about the study drug donanemab

May 23, 2023

  Alicia S. Parker, MD, of The University of Texas Health Science Center at San Antonio, is assistant professor of cognitive and behavioral neurology and clinic director for the health science center’s Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases. The Biggs Institute, in partnership with The University of Texas Rio Grande Valley, is Texas’ […]



Statement by the Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases about the study drug donanemab

May 22, 2023

Media contact: Will Sansom, 210-567-2579, sansom@uthscsa.edu SAN ANTONIO (May 22, 2023) — Alicia S. Parker, MD, of The University of Texas Health Science Center at San Antonio, is assistant professor of cognitive and behavioral neurology and clinic director for the health science center’s Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases. The Biggs Institute, in […]